Lexaria Bioscience Corp (LEXX)

$0.78 -0.03 (-3.34%)
Market Cap 19.16M
Revenue (ttm) 710,000.00
Net Income (ttm) -11.90M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -1,676.06%
Debt to Equity Ratio 0.00
Volume 211,793
Avg Vol 742,754
Day's Range N/A - N/A
Shares Out 24.89M
Stochastic %K 100%
Beta 0.63
Analysts Strong Sell
Price Target $4.50

Company Profile

Lexaria Bioscience Corp. operates as a biotechnology company. The company offers its patented drug delivery-enabling platform technology, DehydraTECH, which combines active pharmaceutical ingredients (APIs) with specific long-chain fatty acid-rich triglyceride oils and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing for improved tolerability while promoting healthier oral ingestion methods. Its DehydraTECH is...

Industry: Biotechnology
Sector: Healthcare
Phone: 250 765 6424
Address:
740 McCurdy Road, Suite 100, Kelowna, Canada
Boston7452
Boston7452 Jan. 14 at 8:39 PM
$LEXX What is this going to do? Get back above support, now resistance at .80, or return to lower support? Need Volume.
0 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 14 at 8:32 PM
$LEXX $DRUG THIS CAN 100% HAPPEN. Same set up...If this gets alerted or pushed so many trader can make money. Their is virtually no risk of dilution or offerings and its in the flings that came out yesterday....FULLY FUNDED THROUGH 2026
1 · Reply
PennyConnection1
PennyConnection1 Jan. 14 at 8:07 PM
$LEXX pushing for that green again
0 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 14 at 7:10 PM
$LEXX Comical watch the scalpers and swingers work the board for their positions back....FOMO must be killing them. I pray heavy volume comes in by an alert or something....Its coming there is nothing in the way of any dilution or offerings in 2026, 99.9% of the risk is off the table...and alot going on to support a run. The CEO letter to shareholders had a ton of clues in it....FOMO is real.
1 · Reply
Boston7452
Boston7452 Jan. 14 at 6:02 PM
$LEXX From the CEO's letter. Management is steadfast in efforts to build value, not support stockprice according to this. Unfortunately building value doesnt translate to current value increasing regardless of how undervalued LEXX is. That said, their quest is to deliver transformative returns for their stakeholders. What that means is protect your position. Hedge, swing, even hold. Whatever you're comfortable doing, but keep watching.
1 · Reply
LOSINGMILLIONS
LOSINGMILLIONS Jan. 14 at 6:00 PM
$LEXX someone selling as 12% down doesn’t mean no selling. Ouch.
1 · Reply
Haridoa
Haridoa Jan. 14 at 5:31 PM
$LEXX Ask: .80 28K
1 · Reply
Haridoa
Haridoa Jan. 14 at 5:30 PM
$LEXX
0 · Reply
Boston7452
Boston7452 Jan. 14 at 5:24 PM
$LEXX The funds that were involved in the last two offerings like reverse splits. They like the tax write offs from their warrants (cost basis harvesting I call it). So if Lex gets that notice, it'll most likely happen. Especially if Lex isnt able to move forward and continues to collate data.
1 · Reply
Shubeedoo
Shubeedoo Jan. 14 at 5:20 PM
$LEXX I agree Rocket, the delisting news means nothing, with all the time given to cure. It does just give another reason for someone to sell. On the bright side, very few sellers and offers are not dropping down just over the bid. Stock is extremely tight!!!
0 · Reply
Latest News on LEXX
Lexaria Releases Annual Letter from the CEO

Jan 12, 2026, 9:10 AM EST - 2 days ago

Lexaria Releases Annual Letter from the CEO

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Dec 30, 2025, 9:20 AM EST - 15 days ago

Lexaria Releases Additional Results from its Successful Phase 1b Study GLP-1-H24-4

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

Dec 23, 2025, 12:06 PM EST - 22 days ago

Lexaria Says Oral GLP-1 Cuts Side Effects Nearly 50% Versus Novo Nordisk's Rybelsus

NVO

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Dec 23, 2025, 9:29 AM EST - 22 days ago

Primary Endpoint Successfully Achieved in Lexaria's Phase 1b Study GLP-1-H24-4

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 16, 2025, 4:00 PM EST - 4 weeks ago

Lexaria Bioscience Corp. Announces Closing of $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Dec 15, 2025, 8:00 AM EST - 4 weeks ago

Lexaria Bioscience Corp. Announces $3.5 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Nov 12, 2025, 9:10 AM EST - 2 months ago

Material Transfer Agreement Between Pharmaceutical Company and Lexaria is Extended

Lexaria Bioscience Corp. Provides Strategic Update

Oct 9, 2025, 9:20 AM EDT - 3 months ago

Lexaria Bioscience Corp. Provides Strategic Update

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 29, 2025, 4:30 PM EDT - 3 months ago

Lexaria Bioscience Corp. Announces Closing of $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Sep 26, 2025, 8:10 AM EDT - 3 months ago

Lexaria Bioscience Corp. Announces $4.0 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Sep 19, 2025, 11:20 AM EDT - 4 months ago

Lexaria's Technology Supports Higher Levels of the GLP-1 Drug Semaglutide in Brain

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Aug 27, 2025, 9:20 AM EDT - 5 months ago

Lexaria Attending the 27th Annual H.C. Wainwright Global Investment Conference

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

Aug 14, 2025, 9:20 AM EDT - 5 months ago

Lexaria's Phase 1b GLP-1 Study Achieves Important "Last Patient Last Visit" Milestone

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Aug 6, 2025, 9:20 AM EDT - 5 months ago

GLP-1 "Arms Race" Broadens to Include Dozens of Companies

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 6 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data From Phase 1b, GLP-1-H24-4 Study

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Jul 28, 2025, 9:25 AM EDT - 6 months ago

Lexaria Provides Positive Interim Results on Partial 8-week Data from Phase 1b, GLP-1-H24-4 Study

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Jul 23, 2025, 9:25 AM EDT - 6 months ago

Lexaria's DehydraTECH Technology Has the Potential to Unlock Accelerated Revenue Growth in the GLP-1-Industry

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Jun 23, 2025, 9:15 AM EDT - 7 months ago

Lexaria Reaches Patent Milestone - 50 Patents Now Granted Worldwide

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Jun 11, 2025, 9:05 AM EDT - 7 months ago

Lexaria's DehydraTECH-Liraglutide Human GLP-1 Clinical Study Supports Pathway to Potential FDA Registration as an Orally-Delivered Capsule

Lexaria Attending BIO International Convention

Jun 5, 2025, 9:20 AM EDT - 7 months ago

Lexaria Attending BIO International Convention

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

May 12, 2025, 9:00 AM EDT - 8 months ago

Lexaria Provides Update on Material Transfer Agreement with Pharmaceutical Company

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Apr 28, 2025, 4:15 PM EDT - 9 months ago

Lexaria Announces Closing of $2 Million Registered Direct Offering of Common Stock

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Apr 25, 2025, 8:00 AM EDT - 9 months ago

Lexaria Announces $2 Million Registered Direct Offering of Common Stock

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Apr 23, 2025, 9:10 AM EDT - 9 months ago

Recent GLP-1-Industry Developments Highlight the Promise of Lexaria Bioscience's Technology

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Apr 3, 2025, 9:10 AM EDT - 10 months ago

Lexaria Updates its Ongoing Human Study GLP-1-H24-4

Lexaria's Human GLP-1 Study #5 Begins Dosing

Apr 2, 2025, 9:05 AM EDT - 10 months ago

Lexaria's Human GLP-1 Study #5 Begins Dosing

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Mar 18, 2025, 9:15 AM EDT - 10 months ago

Lexarias' DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

Mar 18, 2025, 9:15 AM EDT - 10 months ago

Lexaria's DehydraTECH-tirzepatide Oral Capsules Achieve Comparable Levels in Bloodstream as Eli Lilly's Injectable Zepbound(R)

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Feb 27, 2025, 8:00 AM EST - 11 months ago

The Global Revolution in Healthcare Driven by GLP-1 Drugs and the role of Lexaria Bioscience

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Feb 24, 2025, 8:00 AM EST - 11 months ago

Ethics Board Approval Received for DehydraTECH-tirzepatide GLP-1 Study-Arm

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Feb 20, 2025, 8:00 AM EST - 11 months ago

Lexaria's Strategic Business Pursuit of DehydraTECH-Liraglutide

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Feb 11, 2025, 8:00 AM EST - 1 year ago

Lexaria Granted Two New DehydraTECH Patents for Treatment of Epilepsy

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Feb 6, 2025, 9:40 AM EST - 1 year ago

Lexaria Biodistribution Study For DehydraTECH GLP-1 is Underway

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Jan 15, 2025, 9:20 AM EST - 1 year ago

Lexaria's Human GLP-1 Study #5 Receives Independent Review Board Approval

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Jan 14, 2025, 9:10 AM EST - 1 year ago

Lexaria's Oral DehydraTECH-Tirzepatide Reduces Side Effects by Half with Comparable Efficacy Versus Eli Lilly's Injectable GLP-1/GIP Drug Zepbound(R)

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Dec 19, 2024, 9:05 AM EST - 1 year ago

Lexaria's Registered GLP-1 Study #4 Begins Dosing

Lexaria Forms New Scientific Advisory Board

Dec 18, 2024, 9:25 AM EST - 1 year ago

Lexaria Forms New Scientific Advisory Board

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Dec 17, 2024, 9:10 AM EST - 1 year ago

Esteemed Harvard Medical School Professor Dr. Michael Gibson Appointed Chief Medical Advisor at Lexaria Bioscience

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Dec 9, 2024, 9:10 AM EST - 1 year ago

Liraglutide Processed with DehydraTECH to be Studied in Human GLP-1 Study #5

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Nov 26, 2024, 9:20 AM EST - 1 year ago

Revolutionizing Healthcare: Lexaria Highlights Expanding Therapeutic Benefits of GLP-1 Drugs

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

Nov 25, 2024, 9:00 AM EST - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Completes Dosing as Scheduled

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Nov 20, 2024, 9:05 AM EST - 1 year ago

ALL Study Groups using DehydraTECH Processing Outperform Rybelsus(R) in Body Weight Control in Lexaria's 12-Week GLP-1, Diabetes Animal Study

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Nov 14, 2024, 9:10 AM EST - 1 year ago

Lexaria Signs Contract For New DehydraTECH GLP-1 Biodistribution Study

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Nov 13, 2024, 9:20 AM EST - 1 year ago

Ethics Board Approval Granted for Lexaria's 12-Week Phase 1b DehydraTECH GLP-1 Study in Diabetes and Weight Loss

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Nov 7, 2024, 9:15 AM EST - 1 year ago

Lexaria Updates Fast-Moving GLP-1 'Arm's Race' Developments

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 24, 2024, 9:10 AM EDT - 1 year ago

Positive Partial 12-Week Blood Sugar Results from Lexaria's GLP-1 Diabetes Animal Study

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Oct 22, 2024, 9:20 AM EDT - 1 year ago

Positive Partial 12-Week Body Weight Results from Lexaria's GLP-1 Diabetes Animal Study

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 16, 2024, 4:00 PM EDT - 1 year ago

Lexaria Announces Closing of $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Oct 15, 2024, 8:25 AM EDT - 1 year ago

Lexaria Announces $5 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Oct 9, 2024, 9:05 AM EDT - 1 year ago

Lexaria's GLP-1 Human Pilot Study #3 Begins Dosing

Boston7452
Boston7452 Jan. 14 at 8:39 PM
$LEXX What is this going to do? Get back above support, now resistance at .80, or return to lower support? Need Volume.
0 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 14 at 8:32 PM
$LEXX $DRUG THIS CAN 100% HAPPEN. Same set up...If this gets alerted or pushed so many trader can make money. Their is virtually no risk of dilution or offerings and its in the flings that came out yesterday....FULLY FUNDED THROUGH 2026
1 · Reply
PennyConnection1
PennyConnection1 Jan. 14 at 8:07 PM
$LEXX pushing for that green again
0 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 14 at 7:10 PM
$LEXX Comical watch the scalpers and swingers work the board for their positions back....FOMO must be killing them. I pray heavy volume comes in by an alert or something....Its coming there is nothing in the way of any dilution or offerings in 2026, 99.9% of the risk is off the table...and alot going on to support a run. The CEO letter to shareholders had a ton of clues in it....FOMO is real.
1 · Reply
Boston7452
Boston7452 Jan. 14 at 6:02 PM
$LEXX From the CEO's letter. Management is steadfast in efforts to build value, not support stockprice according to this. Unfortunately building value doesnt translate to current value increasing regardless of how undervalued LEXX is. That said, their quest is to deliver transformative returns for their stakeholders. What that means is protect your position. Hedge, swing, even hold. Whatever you're comfortable doing, but keep watching.
1 · Reply
LOSINGMILLIONS
LOSINGMILLIONS Jan. 14 at 6:00 PM
$LEXX someone selling as 12% down doesn’t mean no selling. Ouch.
1 · Reply
Haridoa
Haridoa Jan. 14 at 5:31 PM
$LEXX Ask: .80 28K
1 · Reply
Haridoa
Haridoa Jan. 14 at 5:30 PM
$LEXX
0 · Reply
Boston7452
Boston7452 Jan. 14 at 5:24 PM
$LEXX The funds that were involved in the last two offerings like reverse splits. They like the tax write offs from their warrants (cost basis harvesting I call it). So if Lex gets that notice, it'll most likely happen. Especially if Lex isnt able to move forward and continues to collate data.
1 · Reply
Shubeedoo
Shubeedoo Jan. 14 at 5:20 PM
$LEXX I agree Rocket, the delisting news means nothing, with all the time given to cure. It does just give another reason for someone to sell. On the bright side, very few sellers and offers are not dropping down just over the bid. Stock is extremely tight!!!
0 · Reply
SPYmyQQQ
SPYmyQQQ Jan. 14 at 5:15 PM
🎯 Target Hit 🏁 📨 From Dec 18, 2025 💊 $LEXX 💵 Entry: $0.7001 ✅ Ext: $0.8092 💰 P/L: +15.58% 👉 FREE TRIAL! spymyqqq/join/
0 · Reply
TheRealStockRocket
TheRealStockRocket Jan. 14 at 5:11 PM
$LEXX Who gives an F...that mean nothing, they would be granted a 6 month window to get back over $1.. plus a possible extension of another 6 months. Delisting notice means nothing. Remember last offering in December that closed at a premium of $1.41 a a share...Big investors there. Jan 14, 2026 12:09 PM
1 · Reply
Makingmillions192
Makingmillions192 Jan. 14 at 4:45 PM
$LEXX I’m wheels up for the next 4 hours - give me something exciting to look at when I land ✈️ Let’s hope for another EOD pop wow here 😉
0 · Reply
Shubeedoo
Shubeedoo Jan. 14 at 4:39 PM
$LEXX let’s see if we get that afternoon buying volume again today. Those working the stock, seem to be systematically working it back up towards a dollar. I think they only have till the middle or end of next week to get the stock back above a dollar, before the delisting notice gets sent out. And Long, you have been using that “let’s make a deal” GIF for well over a year now, if not two. But not to worry, even a blind squirrel can find a nut sometimes.
1 · Reply
Boston7452
Boston7452 Jan. 14 at 3:50 PM
$LEXX seems to be pursuing their own CBD formulation with DHT for weight loss market/diabetes, & hypertension market. Technically thats their own drug for these applications. Both markets larger than epilepsy Jazz paid a good chunk for.
1 · Reply
LongLEXX
LongLEXX Jan. 14 at 3:10 PM
$LEXX Anytime!
1 · Reply
Boston7452
Boston7452 Jan. 14 at 2:52 PM
$LEXX not much from my end. Cash burn was only 1m for the quarter so thats good. No debt on balance sheet. All part of them being nimble. Nothing on the revenue side but thats typical of these early stage pharmas until they license their IP.
1 · Reply
PennyConnection1
PennyConnection1 Jan. 14 at 2:39 PM
$LEXX 😂 why is everyone freaking out, anyway…
0 · Reply
Traveller22
Traveller22 Jan. 14 at 2:33 PM
$LEXX they expired this week and are no longer on the cap table.
1 · Reply
DW65
DW65 Jan. 14 at 2:32 PM
$LEXX hell no, just get crapped on all the time.
2 · Reply
Boston7452
Boston7452 Jan. 14 at 2:32 PM
$LEXX delisting their warrants from trading on open market?
0 · Reply
Makingmillions192
Makingmillions192 Jan. 14 at 2:25 PM
$LEXX Looks like we should take back $1 on our own. But I’m expecting upside to be capped there until news.
0 · Reply